This is a well-written article that appeared in a recent New York Times
http://www.nytimes.com/2010/05/17/opinion/17Hotez.html
The author (Peter Hotez) is president of the Sabin Vaccine Institute.
PLoS has an entire journal dedicated to the NTDs:
http://www.plosntds.org/home.action
Tuesday, May 18, 2010
Thursday, May 6, 2010
Global Health Diplomacy
Recently at the GHEC conference in Mexico I heard some talks by Mexican officials who provided their perspective on the recent H1N1 outbreak. It is well worth watching on the Kaiser site (see prior blogs).
Here is the intro to an article (PLoS Medicine) that covers a bit of what they mentioned:
One of the most controversial areas of global health diplomacy over the past five years has involved negotiations to increase equitable access to vaccines for highly pathogenic avian influenza A (H5N1) (HPAI-H5N1) and pandemic 2009 influenza A (H1N1) (2009-H1N1). The limited results produced by these negotiations have stimulated calls for a new global framework to improve equitable access to influenza vaccines. The prospects for such a framework are not, however, promising, because the national interests of most developed states vis-à-vis dangerous influenza strains favor retaining the existing imbalanced, reactive, and ad hoc approach to vaccine access. This article examines why negotiating equitable access to influenza vaccines in the context of HPAI-H5N1 and 2009-H1N1 has been, and promises to continue to be, a difficult diplomatic endeavor.
The full article can be found here.
Here is the intro to an article (PLoS Medicine) that covers a bit of what they mentioned:
One of the most controversial areas of global health diplomacy over the past five years has involved negotiations to increase equitable access to vaccines for highly pathogenic avian influenza A (H5N1) (HPAI-H5N1) and pandemic 2009 influenza A (H1N1) (2009-H1N1). The limited results produced by these negotiations have stimulated calls for a new global framework to improve equitable access to influenza vaccines. The prospects for such a framework are not, however, promising, because the national interests of most developed states vis-à-vis dangerous influenza strains favor retaining the existing imbalanced, reactive, and ad hoc approach to vaccine access. This article examines why negotiating equitable access to influenza vaccines in the context of HPAI-H5N1 and 2009-H1N1 has been, and promises to continue to be, a difficult diplomatic endeavor.
The full article can be found here.
Subscribe to:
Posts (Atom)
Posts
